Melodiol Global Health Ltd.

  • IPO date:
  • Sector: Healthcare
  • GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
  • Industry: Drug Manufacturers - Specialty & Generic
  • Company website

Company description

Melodiol Global Health Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and other health in Europe, Canada, the Asia Pacific, the United States, and internationally. The company develops and commercializes therapeutic products; develops and sells beauty and personal care products under the Green Goo, Southern Butter, and Goodgoo brands; and cultivates, processes, and sells cannabis products. Its products include cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and minerals in a lozenge delivery system; the ImpACTIVE Pro Releaf Stick to provide relief to muscle aches, particularly in professional sport, and acts as an alternative to pharmacological solutions sold through online channels; Ritual Green, a dried flower; Ritual Sticks for pre-rolled joints; and Ritual Gold, a handheld vapouriser. In addition, the company develops Halucenex, which is in phase II clinical trials, which will test the efficacy of psilocybin on treatment of resistant Post Traumatic Stress Disorder. Further, it engages in marketing of its hemp based food, feed supplements, and topical products; manufacture and sale of packaged consumer products; conducts clinical trial and development of synthetic psilocybin micro and macro dose formulations to treat treatment resistant depression and anxiety; and development of psychedelic medicines. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Health Limited in June 2023. Melodiol Global Health Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.

Financial highlights

Market Capitalization$18.6287 million
P/E Ratio
P/E Growth Ratio
Book Value
Dividend Per Share
Earnings Per Share-0.0211
EBITDA
Profit Margin0
Operating Margin TTM0
Return on Assets TTM0
Return on Equity TTM-130.9902
Revenue TTM0

Income statement highlights

All numbers are in thousands

Date Total Revenue Cost of Revenue Gross Profit Total Operating Expenses
2020-12-31 2,448.08 2,303.18 144.9
2021-12-31 6,218.56
2022-12-31 8,773 8,402 371

Balance sheet highlights

All numbers are in thousands

Date Cash Total Assets Total Liabilities Short Term Debt Long Term Debt Common Stock
2020-12-31 19,120.61 5,468.44 3,255.75 71,794.12
2021-12-31 29,314.11 1,555.49 0 109,950.69
2022-12-31 37,982 15,688 0 128,382

Cash flow highlights

All numbers are in thousands

Date Net Income Total Cash Change in Cash Begin period cash End period cash Dividends
2020-12-31 -9,621.58 3,246.77
2021-12-31 -22,377.92 1,137.31
2022-12-31 -17,306 -5,796